
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Yin Yang Huo (Epimedium brevicornu) contains icariin, a flavonoid that inhibits PDE5 enzyme to enhance nitric oxide signaling and improve sexual function. This traditional Chinese herb also supports bone health by promoting osteoblast activity and increasing bone mineral density.

Reported Benefits (Provisional)
Origin & History

Yin Yang Huo, also known as Epimedium brevicornu, is a flowering plant native to China. It is traditionally harvested for its leaves, which are dried and used in herbal preparations.
Research Narrative (Provisional)
Some studies suggest that Yin Yang Huo may improve sexual function and bone health. However, more randomized controlled trials (RCTs) are needed to confirm these effects.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Yin Yang Huo (Epimedium brevicornu) is a medicinal herb rather than a dietary food, so macronutrient content is not nutritionally significant in typical dosage forms. Key bioactive compounds and their approximate concentrations include: Icariin (primary flavonoid glycoside, 0.5–1.5% dry weight in leaves, up to 5% in concentrated extracts) — the principal active constituent responsible for PDE5 inhibition and nitric oxide modulation; Epimedin A, B, and C (flavonoid glycosides, collectively 0.3–1.2% dry weight) — precursors to icariin with synergistic effects; Icariside I and II (icariin metabolites, formed via gut microbial hydrolysis, higher bioavailability than parent icariin due to reduced glycosylation); Baohuoside I (0.1–0.4% dry weight), a flavonol aglycone with strong osteogenic activity. Mineral content per 100g dried herb: Calcium approximately 800–1200 mg, Magnesium 150–250 mg, Zinc 2–5 mg, Iron 10–20 mg, Manganese 3–8 mg, Potassium 400–700 mg. Polysaccharides: approximately 5–10% dry weight, contributing to immunomodulatory effects. Crude fiber: approximately 15–25% dry weight. Protein: approximately 8–12% dry weight, though not consumed in quantities relevant to protein intake. Lignans and sterols are present in trace amounts (<0.1%). Bioavailability notes: Icariin has poor oral bioavailability (~1–5%) in intact form due to its glycoside structure; gut microbiota convert it to icaritin and icariside II, which are more lipophilic and better absorbed. Co-administration with phospholipids or piperine may enhance absorption by 2–3 fold. Standard therapeutic extract doses range from 500 mg to 3 g/day of dried herb equivalent, typically standardized to 10–40% icariin content.
Reported Mechanism (Provisional)
Icariin, the primary bioactive compound, inhibits phosphodiesterase-5 (PDE5) enzyme, leading to increased cyclic GMP levels and enhanced nitric oxide signaling for improved blood flow. The compound also activates bone morphogenetic protein (BMP) signaling pathways and stimulates osteoblast differentiation while inhibiting osteoclast activity. Additionally, icariin modulates testosterone levels by influencing the hypothalamic-pituitary-gonadal axis.
Clinical Narrative (Provisional)
Human clinical trials on Epimedium are limited, with most evidence coming from animal studies and small preliminary human trials. A 12-week study in 108 men with mild erectile dysfunction showed modest improvements in IIEF scores compared to placebo. Animal studies demonstrate bone protective effects with icariin doses of 10-60mg/kg, showing 15-25% increases in bone mineral density. More robust human clinical trials are needed to confirm therapeutic efficacy and establish optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







